Cisapride monohydrate
Based on 2 publication(s) in Google Scholar
Cisapride (R 51619) monohydrate is an orally active, selective 5-HT4 receptor agonist with an EC50 of 140 nM. Cisapride monohydrate also acts as an hERG potassium channel blocker with an IC50 of 9.4 nM. Cisapride monohydrate exerts gastrointestinal prokinetic effects by activating 5-HT4 receptors, but it also blocks the hERG potassium channel responsible for the repolarization phase of cardiac action potentials, delaying repolarization and thus prolonging the action potential duration. Cisapride monohydrate can be used in research related to gastrointestinal dysfunction, gastroesophageal reflux disease, functional dyspepsia, chronic gastritis, gastroparesis, ulcerative colitis and necrotizing enterocolitis.
For research use only. We do not sell to patients.
- Purity : 99.87%
- CAS No.: 260779-88-2
- Formula: C23H31ClFN3O5
- Molecular Weight:483.96
-
Storage:
4°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Publications Citing Use of MedChemExpress (MCE) Cisapride monohydrate
More
Biological Activity
Description
IC50 & Target
[5]|
5-HT4 Receptor 140 nM (EC50) |
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| HEK293 | IC50 |
9.4 nM
|
Inhibition of human ether-a-go-go-related gene (hERG) potassium currents in HEK293 cells stably expressing hERG channels assessed via whole-cell patch-clamp electrophysiological assay with 10 min incubation.
Inhibition of human ether-a-go-go-related gene (hERG) potassium currents in HEK293 cells stably expressing hERG channels assessed via whole-cell patch-clamp electrophysiological assay with 10 min incubation.
|
PMC3408677 |
In Vitro
Cisapride (R 51619) (0.3-30 μM; 500 ms) monohydrate inhibits Kv4.3 potassium channels stably expressed in Chinese hamster ovary cells in a concentration-dependent manner, with an IC50 of 9.8 μM, and accelerates current decay[3].
Cisapride (10 min) monohydrate potently inhibits hERG potassium currents in HEK293 cells stably expressing hERG channels, with an IC50 of 9.4 nM[5].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
Cisapride monohydrate improves intestinal motor function, significantly reduces TNF-α expression in the intestinal mucosa, and alleviates the severity of necrotizing enterocolitis in a mouse model of necrotizing enterocolitis[1].
Cisapride (2-4 mg/kg; once daily; i.p. or p.o.; consecutive dosing for 6 days) monohydrate does not alter the severity of colonic injury in TNBS-induced colitis in male Wistar rats[4].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Wistar rats (male, 200 g, TNBS-induced ulcerative colitis)[5]
-
Dosage:2 mg/kg; 4 mg/kg
-
Administration:i.p., once daily for 6 days; p.o., once daily for 6 days
-
Result:Did not significantly affect the body weight loss and diarrheal status of the rats.
Did not significantly aggravate colonic inflammatory damage macroscopically or microscopically.
Did not significantly alter myeloperoxidase (MPO) activity or proinflammatory cytokine (TNF-α, IL-1β, IL-6) levels in the inflamed colons.
Chemical Information
-
CAS No. 260779-88-2
-
Appearance Solid
-
Molecular Weight 483.96
-
Formula C23H31ClFN3O5
-
Color White to off-white
-
SMILES
ClC1=C(N)C=C(OC)C(C(N[C@H]2[C@@H](OC)CN(CCCOC3=CC=C(F)C=C3)CC2)=O)=C1.O
-
Synonyms
R 51619 monohydrate; (±)-Cisaprid monohydrate
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
4°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Publications (2)
-
Journal Impact Factor
-
Most Recent
-
ACS Omega
Computational Approaches to Identify Molecules Binding to Mycobacterium tuberculosis KasA. [Abstract]2020 Nov 15;5(46):29935-29942. PMID: 33251429 -
Purity & Documentation
-
Data Sheet (289 KB)
-
SDS (476 KB)
- English - EN (476 KB)
- Français - FR (476 KB)
- Deutsch - DE (476 KB)
- Norwegian - NO (476 KB)
- Español - ES (476 KB)
- Swedish - SV (476 KB)
- Italian - IT (476 KB)
- Korean - KR (476 KB)
- Portuguese - PT (476 KB)
-
Handling Instructions (2659 KB)
References
[3]. Sung KW, et al. Effect of mosapride on Kv4.3 potassium channels expressed in CHO cells. Naunyn-Schmiedeberg's archives of pharmacology. 2013 Oct;386(10):905-16. [Content Brief]
[5]. Toga T, et al. The 5-HT(4) agonists cisapride, mosapride, and CJ-033466, a Novel potent compound, exhibit different human ether-a-go-go-related gene (hERG)-blocking activities. J Pharmacol Sci. 2007 Oct;105(2):207-10. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)